Antitumor Effects of IL-6 on Murine Liver Tumor Cells in vivo

Hyung-Sik Kang a  Dae-Ho Cho a  Sung-Sook Kim b  Kwang-Ho Pyun a  Inpyo Choi a

a Immune Cell Signal Transduction Research Unit, Korea Research Institute of Bioscience and Biotechnology, Taejon, and b Department of Pathology, Ulsan University Hospital, Ulsan, Republic of Korea

Key Words
Liver tumor • Interleukin-6 • Antitumor effects • Host immunity

Abstract
IL-6 is a pleiotropic cytokine that is capable of modulating the diverse functions of hepatocytes such as acute phase responses and inflammation in the liver. To learn its antitumor effects in vivo, the cDNA of IL-6 was transfected into murine liver cells, TIB cells. IL-6-transfected TIB cells (TIB73-IL-6 or TIB75-IL-6) produced much higher levels of IL-6 compared with vector-transfected TIB cells (TIB73-vec or TIB75-vec). To investigate the effects of IL-6 on TIB tumor growth in vivo, IL-6-transfected TIB cells or vector-transfected TIB cells were injected subcutaneously into syngeneic mice. Vector-transfected TIB cells grew rapidly 3 weeks after injection, but IL-6-transfected TIB cells did not grow at all for up to 6 weeks. Pathologically, IL-6-transfected TIB cells demonstrated a severe necrosis and apoptotic pattern. Taken together, these results indicate that IL-6 functions as a growth inhibiting factor in vivo, and another biological role of IL-6 in the liver is suggested.

Many cytokines are involved in regulating biophysical homeostasis of the liver. They regulate the biomolecule metabolism, development, and regeneration of liver cells. IL-6 has diverse effects on liver functions including differentiation and inflammation in the liver. Kopf et al. [4] reported that IL-6-deficient mice showed impaired immune and acute phase response, whereas liver failure and defectiveness in hepatocyte regeneration also has been demonstrated in IL-6-deficient mice [2]. These in vivo studies further suggest that IL-6 has an essential role in liver functions. In addition, IL-6 has been reported to induce host immunity to regress tumors such as melanoma [7], lung carcinoma [8], sarcoma [5], and B lymphoma [1].

To test the antitumor effects of IL-6 on liver tumors, human IL-6 cDNA (kindly provided by Dr. T. Kishimoto, Osaka University, Japan) was amplified by polymerase chain reaction with primers containing an Smal restriction site. After cutting with Smal and ligation with Bam HI linker, IL-6 cDNA was subcloned into the Bam HI site of the NeoSRall expression vector [1]. To obtain a stable transfected clone, the IL-6 cDNA was transfected into murine liver tumor cells, TIB73 cells (ATCC TIB73) or TIB75 cells (ATCC TIB75), and selected in 0.75 mg/ml G418 containing medium for three weeks. Subsequently resistant cells were limit-diluted for single cell cloning. TIB73 or TIB75 clones (5 × 10^3) were maintained in...
Fig. 1. Antitumor effects of IL-6 on TIB cells. Constructed pNeoSRall containing IL-6 cDNA was transfected into TIB cells. After selection with 0.75 mg/ml G418, stable TIB73-IL-6 and TIB75-IL-6 cells were obtained. Culture supernatants from normal cells, vector-transfected cells (vec), or TIB-IL-6 cells (IL-6) were tested for IL-6 activity using B9 bioassay (A). Five syngeneic BALB/C mice were injected with $1 \times 10^5$ TIB-vec, TIB73-IL-6 cells (B), or TIB75-IL-6 cells (C). Palpable tumor growth was measured every day up to 46 days after injection. Tumors growing subcutaneously were excised, fixed in formalin, stained with hematoxylin and eosin, and examined by light microscopy. TIB-vec tumors ($\times 400$), well-developed liver cell tumors, were observed (D). TIB-IL-6 tumor ($\times 400$): necrotic and apoptotic cells were observed in the tumor area (E).

RPMI medium containing 10% fetal bovine serum and the culture supernatants were assayed for IL-6 activity using B9 bioassay [3]. IL-6 transfected TIB73 or TIB75 produced more than 20 times the IL-6 as compared with the control or with vector-transfected TIB cells (fig. 1A). Moreover, there was no apparent difference in growth rates between the IL-6 transfectants and control cells (data not shown).

To learn the growth pattern of TIB cells in vivo, $1 \times 10^6$ TIB cells were subcutaneously injected into syngeneic BALB/c mice (6–8 weeks old). Tumor growth was then examined daily and palpable tumors were measured on two perpendicular axes. Tumor volume was calculated assuming spherical growth using the formula, $4/3 \pi r^3$. Three weeks after injection, tumor growth was detectable in the case of control or vector-transfected cells (fig. 1B,